肺腺癌患者PD-L1表达与EGFR突变、Ki-67表达及临床病理特征的相关性OA

Objective:Lung cancer is one of the most prevalent malignancies worldwide,and lung adenocarcinoma is the major subtype of non-small cell lung cancer.Its diagnosis relies on the integrated assessment of molecular biomarkers and clinicopathological features.Programmed death-ligand 1(PD-L1)is a key predictive biomarker for immunotherapy,epidermal growth factor receptor(EGFR)mutations are critical driver alterations for targeted therapy,and Ki-67 reflects tumor proliferative activity.This study aims to investigate the correlation of PD-L1 expression with EGFR mutation,Ki-67 expression,and clinicopathological features in patients with lung adenocarcinoma,providing evidence for precision diagnosis and treatment. Methods:A total of 109 patients with lung adenocarcinoma treated at the Second People's Hospital of Wuhu City from December 2023 to December 2024 were retrospectively analyzed.EGFR mutations were detected using next-generation sequencing(NGS),while PD-L1 and Ki-67 expression were assessed by immunohistochemistry. Results:Among the 109 patients,the positive expression rate of PD-L1 was 45%.PD-L1 expression was significantly associated with tumor differentiation,tumor size,and Ki-67 proliferation index(P<0.05).Multivariate Logistic regression analysis showed that tumor differentiation and tumor size were independent factors influencing PD-L1 expression.The EGFR mutation rate was 65.1%,with exon 19 deletions and exon 21 L858R mutations being the predominant mutation types.EGFR mutations were more frequently observed in female patients and those without a smoking history,and were significantly associated with lymph node metastasis and Ki-67 expression(all P<0.05). Conclusion:In lung adenocarcinoma,PD-L1 expression is associated with tumor size and differentiation but shows no significant correlation with EGFR mutation status,suggesting that tumor burden may play a key role in regulating PD-L1 expression.